Q1 2026 Pelthos Therapeutics Inc Earnings Call Transcript

May 14, 2026 / 12:30 PM GMT

Release Date Price: $27.69 (+6.46%)

Transcript 8-K10-Q

Key Points

Positve

Pelthos Therapeutics Inc (PTHS) experienced substantial revenue growth, with a 17% increase in net product revenue from Q4 2025 to Q1 2026.
The company successfully expanded its sales force from 50 to 64 representatives, enhancing its market reach.
ZelSUDME, the lead product, saw a 25% increase in prescription units, indicating strong market acceptance.
Pelthos Therapeutics Inc (PTHS) secured a $50 million term debt loan, strengthening its balance sheet and supporting future growth.
The company has a strong coverage rate for ZelSUDME, with 59% coverage for commercial insurance plans and 99% for Medicaid.

Negative

Pelthos Therapeutics Inc (PTHS) reported a net loss of $10.2 million for Q1 2026, highlighting ongoing financial challenges.
The cost of goods sold remained high at $1.7 million, with inventory write-offs impacting financials.
SG&A expenses increased by 14% from Q4 2025 to Q1 2026, driven by personnel costs and marketing expenses.
Interest expenses rose to $2.4 million in Q1 2026, reflecting the financial burden of existing convertible notes and loan facilities.
The company faces uncertainties regarding the timing and impact of potential new contracts, which could affect gross-to-net ratios.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PTHS.A - Pelthos Therapeutics Inc
Q1 2026 Pelthos Therapeutics Inc Earnings Call
May 14, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good morning and welcome to the Peltos Therapeutics 2026 First Quarter Financial Results Conference Call.

At this time, all participants are in listen-only mode.

A brief question-and-answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please signal the operator by pressing and 0 on your telephone keypad.

As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mike Moyer, from LifeSci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.